516 related articles for article (PubMed ID: 28682870)
1. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis.
Li J; Shao YH; Wang XG; Gong Y; Li C; Lu Y
Endocr J; 2018 Mar; 65(3):335-344. PubMed ID: 29375082
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
7. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
8. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Łopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
10. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
[TBL] [Abstract][Full Text] [Related]
11. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Zhang Q; Dou J; Lu J
Diabetes Res Clin Pract; 2014 Sep; 105(3):313-21. PubMed ID: 25015317
[TBL] [Abstract][Full Text] [Related]
12. Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials.
Farahani P
J Popul Ther Clin Pharmacol; 2017 May; 24(2):e32-e40. PubMed ID: 28594482
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
16. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
17. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis.
Jingfan Z; Ling L; Cong L; Ping L; Yu C
Arch Endocrinol Metab; 2019; 63(5):478-486. PubMed ID: 31271575
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
